BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 9,892,226 shares of BridgeBio Pharma, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficially owning 9,892,226 shares of BridgeBio Pharma common stock.
  • Percent of class: The reported holdings represent 5.1% of BridgeBio Pharma's outstanding common shares, according to the filing.
  • Sole voting power: BlackRock disclosed sole voting power over 9,576,011 shares, with shared voting power of zero.
  • Sole dispositive power: BlackRock reported sole dispositive power over 9,892,226 shares, with shared dispositive power of zero.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • No single person above 5%: The filing states that no one person's interest in BridgeBio Pharma common stock exceeds five percent of total outstanding common shares among those for whom BlackRock holds the shares.

BlackRock's Schedule 13G Disclosure on BridgeBio Pharma Common Stock

BlackRock, Inc., organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, filed a Schedule 13G to report its beneficial ownership position in BridgeBio Pharma, Inc. (CUSIP 10806X102), whose principal executive offices are located at 421 Kipling Street, Palo Alto, CA 94301. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, with the triggering event date listed as September 30, 2026.

According to the filing, BlackRock reported aggregate beneficial ownership of 9,892,226 shares of BridgeBio Pharma common stock, representing 5.1% of the class. Of those shares, BlackRock disclosed sole voting power over 9,576,011 shares and sole dispositive power over the full 9,892,226 shares. Both shared voting power and shared dispositive power were reported as zero.

The filing notes that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it does not include securities, if any, beneficially owned by other business units whose ownership has been disaggregated in accordance with SEC Release No. 34-39538. BlackRock filed as a parent holding company or control person, and subsidiary identification information is provided in Exhibit 99 attached to the filing. BlackRock certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. disclosed a 5.1% beneficial ownership stake in BridgeBio Pharma, Inc., totaling 9,892,226 shares of common stock, with the event date of September 30, 2026, reported via Schedule 13G filed on October 27, 2026.